In April 2022, FDA issued proposed product standards banning menthol flavoring in cigarettes and cigars; however, the benefits of these product standards could be weakened by the role of substitute products still available in the market.
In a study published in Science, UCSF researchers Kevin Lou, Luke Gilbert, and Kevan Shokat demonstrated the discovery of a cellular uptake pathway important for large and complex molecules, which bind in unconventional ways to their targets and are efficiently taken up by target cells.
Cancer Research UK, The University of Manchester, and Roche Products Ltd. opened a multi-drug, precision medicine trial for people with rare cancers who need more treatment options. The trial is set up to recruit both pediatric and adult patients with any rare cancer type.
Topline results from the pivotal phase III KEYNOTE-859 trial investigating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, were positive.
Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.
New research out of VCU Massey Cancer Center suggests that the inactivation of NF1—a gene known as Neurofibromin-1 that holds natural tumor-suppressing functions—could be instrumental in the onset of pancreatic cancer, either in tandem with KRAS mutations, which occur in 85-90% of all pancreatic tumors, or even before any mutations occur in the KRAS gene, in partnership with TP53, the most inactivated tumor suppressor gene in human malignancies.
The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center implemented an approach to post-surgery pain management that is focused on maximizing non-opioid techniques first, using opioids only as a back-up option.
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and colleagues showed that these treatments could also reduce the risk of dying from the disease in women who are at high risk.
Johns Hopkins researchers generate lab-grown human tissue model for gastroesophageal junction cancer
Researchers at Johns Hopkins Medicine have created a laboratory-grown three-dimensional organoid model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction.
Researchers from Roswell Park Comprehensive Cancer Center and Gero and Genome Protection Inc., recently published new work in Nature Communications in which the artificial neural network applied by the research team precisely projected the health condition of an aging mouse with the help of a single variable, which was termed dynamic frailty indicator (dFI) that accurately characterizes the damage that an animal accumulates throughout life.
